Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nutrient control of splice site selection contributes to methionine addiction of cancer. | Mol Metab | 2025 | 39862967 | PubTator, text mining | PubMed |
| Update on the Progress of Musashi-2 in Malignant Tumors. | Front Biosci (Landmark Ed) | 2025 | 39862069 | PubTator, text mining | PubMed |
| Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. | Leukemia | 2025 | 39856223 | PubTator, text mining | PubMed |
| The Role of WDR77 in Cancer: More than a PRMT5 Interactor. | Mol Cancer Res | 2025 | 39853175 | PubTator, text mining | PubMed |
| Discovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening. | ACS Omega | 2025 | 39829491 | PubTator, text mining | PubMed |
| Biomedical effects of protein arginine methyltransferase inhibitors. | J Biol Chem | 2025 | 39826691 | PubTator, text mining | PubMed |
| An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy. | Hum Pathol | 2025 | 39824298 | PubTator, text mining | PubMed |
| Resveratrol as a BCL6 natural inhibitor suppresses germinal center derived Non-Hodgkin lymphoma cells growth. | J Nat Med | 2025 | 39815148 | PubTator, text mining | PubMed |
| PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. | J Exp Clin Cancer Res | 2025 | 39794830 | PubTator, text mining | PubMed |
| Substrate adaptors are flexible tethering modules that enhance substrate methylation by the arginine methyltransferase PRMT5. | J Biol Chem | 2025 | 39793893 | PubTator, text mining | PubMed |
| Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity. | J Med Chem | 2025 | 39787362 | PubTator, text mining | PubMed |
| PRMT5-Mediated ALKBH5 Methylation Promotes Colorectal Cancer Immune Evasion via Increasing CD276 Expression. | Research (Wash D C) | 2025 | 39781264 | PubTator, text mining | PubMed |
| Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma. | J Gastrointest Cancer | 2025 | 39762686 | PubTator, text mining | PubMed |
| TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. | Transl Oncol | 2025 | 39756156 | PubTator, text mining | PubMed |
| Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma. | J Med Chem | 2025 | 39722476 | PubTator, text mining | PubMed |
| Shedding light on imaging cancer research: Design and synthesis of 1, 8-naphthalimide-based PRMT5-targeted fluorescent ligands. | Bioorg Chem | 2025 | 39708553 | PubTator, text mining | PubMed |
| Magnesium-dependent-protein phosphatase 1B regulates the protein arginine methyltransferase 5 through the modulation of myosin phosphatase. | J Biol Chem | 2025 | 39706272 | PubTator, text mining | PubMed |
| PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells. | Oncogene | 2025 | 39695328 | PubTator, text mining | PubMed |
| JBP1 and JBP3 have conserved structures but different affinity to base-J. | J Struct Biol | 2025 | 39674235 | PubTator, text mining | PubMed |
| Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment. | Gut | 2025 | 39642967 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=18